Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2013

Open Access 01-12-2013 | Research article

Characteristics of users and implications for the use of complementary and alternative medicine in Ghanaian cancer patients undergoing radiotherapy and chemotherapy: a cross- sectional study

Authors: Joel Yarney, Andrew Donkor, Samuel Y Opoku, Lily Yarney, Isaac Agyeman-Duah, Alice C Abakah, Emmanuel Asampong

Published in: BMC Complementary Medicine and Therapies | Issue 1/2013

Login to get access

Abstract

Background

There is widespread use of Complementary and Alternative Medicine (CAM) in Ghana, driven by cultural consideration and paradigm to disease causation. Whether there is concurrent use of conventional medicine and CAM in cancer patients is unknown. This study investigates the prevalence, pattern and predictors of CAM use in cancer patients. Overlapping toxicity, sources of information, and whether users inform their doctor about CAM use is examined.

Method

Cross-sectional study using a questionnaire administered to cancer patients, who were receiving radiotherapy and or chemotherapy or had recently completed treatment at a single institution was used.

Results

Ninety eight patients participated in the study with a mean age of 55.5 (18–89), made up of 51% females. Married individuals formed 56% of the respondents, whilst 49% had either secondary or tertiary education. Head and neck cancer patients were 15.3%, breast (21.4%), abdomen/pelvic cancers constituted (52%).Seventy seven (78.6%) patients received radiotherapy only, 16.3% received radiation and chemotherapy and 5.3% had chemotherapy only.
Ninety five patients were diagnosed of cancer within the past 24 months,73.5% were CAM users as follows; massage(66.3%), herbal(59.2%), mega vitamins(55.1%), Chinese medicine(53.1%),and prayer(42.9%). Sixty eight percent were treated with curative intent. Overlapping toxicity was reported. Majority (83.3%) of users had not informed their doctor about CAM use.
On univariate analysis, female (p=0.004) and palliative patients, p=0.032 were more likely to be CAM users. Multivariate analysis identified female (p<0.01), as significant for use, whilst head and neck site was significant for non use (p<0.028). Young, married and highly educated individuals are more likely to use CAM.
Friends and Media are the main sources of information on CAM. There was increase in CAM use after the diagnosis of cancer mainly for Chinese Medicine and vitamins.

Conclusion

There is high CAM usage among Cancer patients, comparable to use in the general population, there is concurrent use of CAM and conventional medicine with reported overlapping toxicity but without informing Oncologist about use. Women and palliative patients are more likely to use CAM. Doctor patient communication on herbal-radiotherapy and drug treatment interaction needs to be strengthened. Standardization and regulation of CAM use is paramount.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ernst E, Resch KL, Mills S: Complimentary medicine- a definition. Br J Gen Pract. 1995, 45: 506-PubMedCentral Ernst E, Resch KL, Mills S: Complimentary medicine- a definition. Br J Gen Pract. 1995, 45: 506-PubMedCentral
2.
go back to reference Ernst E: Coplementary cancer treatment: hope or hazard?. Clin Oncol. 1995, 7: 259-263. 10.1016/S0936-6555(05)80616-8.CrossRef Ernst E: Coplementary cancer treatment: hope or hazard?. Clin Oncol. 1995, 7: 259-263. 10.1016/S0936-6555(05)80616-8.CrossRef
4.
go back to reference De Graft Aikins A, Anum A, Agyepong C, Addo J, Ogedegbe O: Lay representation of chronic disease in Ghana: implication for primary prevention. Ghana Med J. 2012, 46 (2): 59-68.PubMedPubMedCentral De Graft Aikins A, Anum A, Agyepong C, Addo J, Ogedegbe O: Lay representation of chronic disease in Ghana: implication for primary prevention. Ghana Med J. 2012, 46 (2): 59-68.PubMedPubMedCentral
5.
go back to reference Ferlay J, Bray F, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5. 2001, Lyon: IARC Press Ferlay J, Bray F, Parkin DM: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Cancer Base No. 5. 2001, Lyon: IARC Press
7.
go back to reference Brenner H, Gondos A, Arndt V: Recent major progress in long-term cancer patient survival disclosed by modelled period analysis. J Clin Oncol. 2007, 25 (22): 3274-3280. 10.1200/JCO.2007.11.3431.CrossRefPubMed Brenner H, Gondos A, Arndt V: Recent major progress in long-term cancer patient survival disclosed by modelled period analysis. J Clin Oncol. 2007, 25 (22): 3274-3280. 10.1200/JCO.2007.11.3431.CrossRefPubMed
9.
go back to reference Clegg- Lamptey J, Dakubo J, Attobra YN: Why do breast cancer patients report late or abscond during treatment in Ghana? A pilot study. Ghana Med J. 2009, 43 (3): 127-131.PubMedPubMedCentral Clegg- Lamptey J, Dakubo J, Attobra YN: Why do breast cancer patients report late or abscond during treatment in Ghana? A pilot study. Ghana Med J. 2009, 43 (3): 127-131.PubMedPubMedCentral
10.
go back to reference Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998, 16: 3649-3655.PubMed Miller DR, Anderson GT, Stark JJ, Granick JL, Richardson D: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol. 1998, 16: 3649-3655.PubMed
11.
go back to reference Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group: Evaluation of shark cartilage in patients with advanced cancer; a North Central Cancer Treatment group trial. Cancer. 2005, 104: 176-182. 10.1002/cncr.21107.CrossRefPubMed Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP, North Central Cancer Treatment Group: Evaluation of shark cartilage in patients with advanced cancer; a North Central Cancer Treatment group trial. Cancer. 2005, 104: 176-182. 10.1002/cncr.21107.CrossRefPubMed
12.
go back to reference Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB: Should supplement antioxidant administration be avoided during chemotherapy and radiation therapy?. J Natl Cancer Inst. 2008, 4: 100(11)- Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB: Should supplement antioxidant administration be avoided during chemotherapy and radiation therapy?. J Natl Cancer Inst. 2008, 4: 100(11)-
13.
go back to reference Ezeome ER, Anarado AN: Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. BMC Complement Altern Med. 2007, 7: 28-10.1186/1472-6882-7-28.CrossRefPubMedPubMedCentral Ezeome ER, Anarado AN: Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. BMC Complement Altern Med. 2007, 7: 28-10.1186/1472-6882-7-28.CrossRefPubMedPubMedCentral
14.
go back to reference Chang KH, Brodie R, Choong MA, Sweeney KJ, Kerin M: Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals. BMC Cancer. 2011, 11: 196-10.1186/1471-2407-11-196.CrossRefPubMedPubMedCentral Chang KH, Brodie R, Choong MA, Sweeney KJ, Kerin M: Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals. BMC Cancer. 2011, 11: 196-10.1186/1471-2407-11-196.CrossRefPubMedPubMedCentral
15.
go back to reference Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000, 18 (13): 2505-2514.PubMed Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE: Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol. 2000, 18 (13): 2505-2514.PubMed
16.
go back to reference Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AMA, Platin N, Kearney N: Use of complementary and alternative medicine in cancer patients: a European survey. Annals of Oncol. 2005, 16: 655-663. 10.1093/annonc/mdi110.CrossRef Molassiotis A, Fernadez-Ortega P, Pud D, Ozden G, Scott JA, Panteli V, Margulies A, Browall M, Magri M, Selvekerova S, Madsen E, Milovics L, Bruyns I, Gudmundsdottir G, Hummerston S, Ahmad AMA, Platin N, Kearney N: Use of complementary and alternative medicine in cancer patients: a European survey. Annals of Oncol. 2005, 16: 655-663. 10.1093/annonc/mdi110.CrossRef
17.
go back to reference Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer. Cancer. 1998, 83 (4): 777-782. 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O.CrossRefPubMed Ernst E, Cassileth BR: The prevalence of complementary/alternative medicine in cancer. Cancer. 1998, 83 (4): 777-782. 10.1002/(SICI)1097-0142(19980815)83:4<777::AID-CNCR22>3.0.CO;2-O.CrossRefPubMed
18.
go back to reference Patterson RE, Neuhouser ML, Hedderson MM: Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med. 2002, 8: 477-485. 10.1089/107555302760253676.CrossRefPubMed Patterson RE, Neuhouser ML, Hedderson MM: Types of alternative medicine used by patients with breast, colon, or prostate cancer: predictors, motives, and costs. J Altern Complement Med. 2002, 8: 477-485. 10.1089/107555302760253676.CrossRefPubMed
19.
go back to reference Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, Slevin ML: Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ. 1994, 309: 86-89. 10.1136/bmj.309.6947.86.CrossRefPubMedPubMedCentral Downer SM, Cody MM, McCluskey P, Wilson PD, Arnott SJ, Lister TA, Slevin ML: Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ. 1994, 309: 86-89. 10.1136/bmj.309.6947.86.CrossRefPubMedPubMedCentral
20.
go back to reference Ceylan S, Hamazaoglu O, Komurcu S, Beyan C, Yalcin A: Survey of the use of complementary and alternative medicine among Turkish cancer patients. Complement Ther Med. 2002, 10: 94-99. 10.1054/ctim.2002.0527.CrossRefPubMed Ceylan S, Hamazaoglu O, Komurcu S, Beyan C, Yalcin A: Survey of the use of complementary and alternative medicine among Turkish cancer patients. Complement Ther Med. 2002, 10: 94-99. 10.1054/ctim.2002.0527.CrossRefPubMed
21.
go back to reference Shen J, Wenger N, Glaspy J: Electroacupuncture for control of myeloablative chemotherapy induced emesis: a randomized controlled trial. J Am Med Assoc. 2000, 284: 2755-2761. 10.1001/jama.284.21.2755.CrossRef Shen J, Wenger N, Glaspy J: Electroacupuncture for control of myeloablative chemotherapy induced emesis: a randomized controlled trial. J Am Med Assoc. 2000, 284: 2755-2761. 10.1001/jama.284.21.2755.CrossRef
22.
go back to reference Pan CX, Morrison RS, Ness J: Complementary and alternative medicine in the management of pain, dyspneoa, and nausea and vomiting near end of life. a systematic review. J Pain Symptom Manage. 2000, 20: 374-387. 10.1016/S0885-3924(00)00190-1.CrossRefPubMed Pan CX, Morrison RS, Ness J: Complementary and alternative medicine in the management of pain, dyspneoa, and nausea and vomiting near end of life. a systematic review. J Pain Symptom Manage. 2000, 20: 374-387. 10.1016/S0885-3924(00)00190-1.CrossRefPubMed
23.
go back to reference Fellowes D, Barnes K, Wilkinson S: Aromatherapy and massage for symptom relief inpatients with cancer. Cochrane Database Syst Rev. 2004, CD002287- Fellowes D, Barnes K, Wilkinson S: Aromatherapy and massage for symptom relief inpatients with cancer. Cochrane Database Syst Rev. 2004, CD002287-
25.
go back to reference Ko RJ: Adulterants in Asian patent medicines. N England J Med. 1998, 339: 847-CrossRef Ko RJ: Adulterants in Asian patent medicines. N England J Med. 1998, 339: 847-CrossRef
26.
go back to reference Murch SJ, Krishna Raj S, Saxena PK: Phytopharmaceuticals: problems, limitations, and solutions. SciRev Alternat Med. 2000, 4: 33-37. Murch SJ, Krishna Raj S, Saxena PK: Phytopharmaceuticals: problems, limitations, and solutions. SciRev Alternat Med. 2000, 4: 33-37.
27.
go back to reference Drew AK, Myers SP: Safety Issues in herbal medicines: implications for the health professional. Med J Aust. 1997, 166: 538-541.PubMed Drew AK, Myers SP: Safety Issues in herbal medicines: implications for the health professional. Med J Aust. 1997, 166: 538-541.PubMed
28.
go back to reference Ang-Lee MK, Moss J, Yuan CS: Herbal medicines and perioperative care. JAMA. 2001, 286: 208-216. 10.1001/jama.286.2.208.CrossRefPubMed Ang-Lee MK, Moss J, Yuan CS: Herbal medicines and perioperative care. JAMA. 2001, 286: 208-216. 10.1001/jama.286.2.208.CrossRefPubMed
29.
go back to reference Gyasi RM, Mensah CM, Adjei PO, Agyeman S: Public perceptions of the role of traditional medicine in the health care delivery system in Ghana. Glob J Health Sci. 2011, 3 (2): 40-49. Gyasi RM, Mensah CM, Adjei PO, Agyeman S: Public perceptions of the role of traditional medicine in the health care delivery system in Ghana. Glob J Health Sci. 2011, 3 (2): 40-49.
30.
go back to reference Lippman SM, Klein EA, Goodman PJ: Effect of selenium and vitamin E on risk of prostate cancer and others: the Selinium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009, 301 (1): 39-51. 10.1001/jama.2008.864.CrossRefPubMed Lippman SM, Klein EA, Goodman PJ: Effect of selenium and vitamin E on risk of prostate cancer and others: the Selinium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009, 301 (1): 39-51. 10.1001/jama.2008.864.CrossRefPubMed
31.
go back to reference Davis EL, Oh B, Butow PN, Mullan BA, Clarke S: Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist. 2012, 17 (11): 1475-1481. 10.1634/theoncologist.2012-0223.CrossRefPubMedPubMedCentral Davis EL, Oh B, Butow PN, Mullan BA, Clarke S: Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review. Oncologist. 2012, 17 (11): 1475-1481. 10.1634/theoncologist.2012-0223.CrossRefPubMedPubMedCentral
32.
go back to reference Kristoffersen AE, Fonnebo V, Northeim AJ: Do cancer patients with a por prognosis use complementary and alternative medicine more often than others?. J Altern Complement Med. 2009, 14: 1115-1120. Kristoffersen AE, Fonnebo V, Northeim AJ: Do cancer patients with a por prognosis use complementary and alternative medicine more often than others?. J Altern Complement Med. 2009, 14: 1115-1120.
33.
go back to reference Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ: Buyer beware? Does the information provided with herbal products available over the counter enable safe use?. BMC Med. 2011, 9: 94-10.1186/1741-7015-9-94.CrossRefPubMedPubMedCentral Raynor DK, Dickinson R, Knapp P, Long AF, Nicolson DJ: Buyer beware? Does the information provided with herbal products available over the counter enable safe use?. BMC Med. 2011, 9: 94-10.1186/1741-7015-9-94.CrossRefPubMedPubMedCentral
Metadata
Title
Characteristics of users and implications for the use of complementary and alternative medicine in Ghanaian cancer patients undergoing radiotherapy and chemotherapy: a cross- sectional study
Authors
Joel Yarney
Andrew Donkor
Samuel Y Opoku
Lily Yarney
Isaac Agyeman-Duah
Alice C Abakah
Emmanuel Asampong
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2013
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/1472-6882-13-16

Other articles of this Issue 1/2013

BMC Complementary Medicine and Therapies 1/2013 Go to the issue